Whole Genome Sequencing Identifies Myeloma Precursor Conditions

Francesco Maura, MD, discusses the significance of studying genomic defining events in patients with multiple myeloma.

Ola Landgren, MD, PhD, discusses the rationale behind examining whole-genome sequencing in smoldering myeloma.

Whole-genome sequencing has the potential to accurately differentiate between stable and progressive precursor conditions to multiple myeloma in low disease burden clinical states and the use of this technology in the clinic may result in a significant shift in the management of these patients.

Ola Landgren, MD, PhD, and Francesco Maura, MD, discuss their research with whole-genome sequencing in patients with precursor conditions, and spotlight next steps for research.